[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353228-105":59,"doc-detail-353228-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp1-bcat2-axis-upregulates-abcg1-via-histone-lactylation-to-drive-acquired-parp-inhibitor-resistance-in-prostate-cancer","PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer","","PARPi resistance poses a major challenge in prostate cancer. Although branched-chain amino acid (BCAA) metabolism is implicated in cancer biology, its specific contribution to PARPi resistance is unclear. This study compares BCAA and BCAT2 levels between PARPi-resistant and -sensitive models and evaluates clinical relevance. Mechanistic experiments in vitro and in vivo use RNA sequencing, metabolomics, RIP, ChIP, and CUT&Tag to define how BCAT2-driven histone lactylation supports resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp1-bcat2-axis-upregulates-abcg1-via-histone-lactylation-to-drive-acquired-parp-inhibitor-resistance-in-prostate-cancer/353228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp1-bcat2-axis-upregulates-abcg1-via-histone-lactylation-to-drive-acquired-parp-inhibitor-resistance-in-prostate-cancer/353228.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in prostate cancer?","Question",{"text":112,"@type":113},"The study addresses acquired resistance to PARP inhibitors (PARPi) in prostate cancer and aims to clarify its underlying metabolic drivers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers connect BCAT2 to PARPi resistance?",{"text":117,"@type":113},"They compared BCAA/BCAT2 levels between PARPi-resistant and PARPi-sensitive models, then used functional and mechanistic assays (RIP, ChIP, CUT&Tag, metabolomics) to show BCAT2’s role in resistance pathways.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links BCAT2 to increased resistance?",{"text":121,"@type":113},"BCAT2 promotes ABCG1 transcription by enhancing glycolysis and lactate secretion, which increases histone H3K18la lactylation; PARP1 trapping weakens PARP1–BCAT2 mRNA interaction, increasing BCAT2 and supporting resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353228,1790211807,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Mei et al. Journal of Experimental & Clinical Cancer Research (2026) 45:149 [https://doi.org/10.1186/s13046-026-03719-1](https://doi.org/10.1186/s13046-026-03719-1)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nPARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer  \nWangli Mei1†, Hang Zhou1†, Weiyi Li1†, Yongqiang Liu3†, Chaozhi Tang1, Mengyu Wei3, Zhen Zhou1, Bowen Ye1, Hanwen Niu1, Weitian Wang1, Kaiqi Yang1, Yue Zhang4, Liqun Huang2*, Yang Yu3*, Xiaofei Wen2* and Lin Ye1*  \nAbstract  \nBackground Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in prostate cancer (PCa) . Although branched-chain amino acid (BCAA) metabolism is implicated in cancer biology, its specific role in PARPi resistance remains unclear. This study aims to investigate how BCAA metabolism contributes to PARPi resistance in PCa.  \nMethods We compared BCAA and Branched-Chain Amino Acid Aminotransferase 2 (BCAT2) levels between PARPiresistant and PARPi-sensitive cell lines and assessed their clinical relevance. Functional studies were conducted in vitro and in vivo using cell and mouse models. Mechanistic assays, including RNA sequencing, metabolomics, RNAbinding protein immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), and Cleavage Under Targets and Tagmentation (CUT&Tag), were used to delineate BCAT2-mediated PARPi resistance.  \nResults BCAT2 expression correlated with PARPi resistance in PCa, and increased BCAA/BCAT2 levels in PARPi-resistant tissues were associated with reduced patient survival. Mechanistically, the DNA-binding domain (DBD) of PARP1 directly bound BCAT2 mRNA and regulated its stability; PARPi-induced PARP1 trapping weakened this interaction, increased BCAT2 expression, and promoted resistance. Transcriptomic and energy-metabolism analyses indicated that BCAT2 enhanced ABCG1 transcription by augmenting glycolysis and lactate secretion, thereby increasing histone H3K18la lactylation. These findings support a PARP1–BCAT2–ABCG1 axis in PARPi resistance. Combining a BCAT2 inhibitor with PARPi produced synergistic effects in cell line–derived xenografts (CDXs) and patient-derived organoids (PDOs) .  \n†Wangli Mei, Hang Zhou, Weiyi Li and Yongqiang Liu contributed equally to this work.  \n*Correspondence:  \nLiqun Huang [huang.liqun@zsgmc.sh.cn](huang.liqun@zsgmc.sh.cn)[ ](huang.liqun@zsgmc.sh.cn)Yang Yu [yyshdsyy@163.com](yyshdsyy@163.com)[ ](yyshdsyy@163.com)Xiaofei Wen [wen.xiaofei@zsgmc.sh.cn](wen.xiaofei@zsgmc.sh.cn)[ ](wen.xiaofei@zsgmc.sh.cn)Lin Ye [ericyelin@tongji.edu.cn](ericyelin@tongji.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, u","cbCainZCgG9N9fTa","https://ap.wps.com/l/cbCainZCgG9N9fTa","pdf",3845076,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Keywords\n# Introduction and background\n## Prostate cancer burden and challenges\n## PARP inhibitors and mechanisms of acquired resistance\n## Metabolic reprogramming and BCAA metabolism","[{\"question\":\"What problem does the study address in prostate cancer?\",\"answer\":\"The study addresses acquired resistance to PARP inhibitors (PARPi) in prostate cancer and aims to clarify its underlying metabolic drivers.\"},{\"question\":\"How did the researchers connect BCAT2 to PARPi resistance?\",\"answer\":\"They compared BCAA/BCAT2 levels between PARPi-resistant and PARPi-sensitive models, then used functional and mechanistic assays (RIP, ChIP, CUT\\u0026Tag, metabolomics) to show BCAT2’s role in resistance pathways.\"},{\"question\":\"What mechanism links BCAT2 to increased resistance?\",\"answer\":\"BCAT2 promotes ABCG1 transcription by enhancing glycolysis and lactate secretion, which increases histone H3K18la lactylation; PARP1 trapping weakens PARP1–BCAT2 mRNA interaction, increasing BCAT2 and supporting resistance.\"}]","PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer | PDF",1790103706,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbaf648fa1a56ccf5dfea5c2887a20cc.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94800efaaaa4b597cd8b35c9fdea7170.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b6b4012358d1de28c80abafd58e1c21.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24f2f13b72adb7dcbe8dc180a715fd63.webp",980,1306]